Personalized cancer vaccine with standard therapy for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III triple-negative breast cancer.
- You are scheduled to receive chemotherapy (a type called anthracycline/taxane) and an immunotherapy drug (PD-1 inhibitor) before surgery.
- Your tumor is reachable for a biopsy, and the biopsy sample must have at least 30% cancer cells.
- You are 18 or older and in generally good health (able to care for yourself, ECOG score 0–2).
- You do not have an active autoimmune disease or other serious medical condition that could interfere with the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine designed to train your immune system to fight triple negative breast cancer. It is for people who are already receiving or about to receive the standard KEYNOTE 522 treatment, and the vaccine is given after a few months of that treatment.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.